Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
NCT ID: NCT01692873
Last Updated: 2018-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
274 participants
INTERVENTIONAL
2012-02-29
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month.
The aim of this study is the identification of diagnosis biomarkers, predictive of the therapeutic response.
This project investigate the use of molecular analyses applied to pancreatic tumor cells collected by microbiopsy under ultrasound-endoscopy, and blood cells.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Detection of Pancreatic Cancer in Patients With Papillary and Mucinous Intracanal Tumours of the Pancreas Papillary and Mucinous Tumours of the Pancreas
NCT06000553
Changes in Biomarkers From Blood Over Time in Patients With Pancreatic Adenocarcinoma
NCT02974764
Prospective Monocentric Clinical-biological Database
NCT04136132
Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
NCT03536793
Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer
NCT07271823
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
suspected pancreatic tumor
Realization of pancreatic tumor biopsy and blood samples
suspected pancreatic tumor
Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
suspected pancreatic tumor
Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient \> 18 years old
* Social Security affiliation
* Signed informed consent
Exclusion Criteria
* Major person being the object of a legal protective measure or unable to express its consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Paoli-Calmettes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marine GILABERT, MD
Role: PRINCIPAL_INVESTIGATOR
Institut Paoli-Calmettes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Marine GILABERT, MD
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fraunhoffer NA, Abuelafia AM, Chanez B, Bigonnet M, Gayet O, Roques J, Chuluyan E, Dusetti N, Iovanna J. Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Cancer Commun (Lond). 2022 Nov;42(11):1212-1216. doi: 10.1002/cac2.12365. Epub 2022 Sep 30. No abstract available.
Fraunhoffer NA, Abuelafia AM, Dusetti N, Iovanna J. Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool. Cancer Commun (Lond). 2022 Oct;42(10):1028-1031. doi: 10.1002/cac2.12335. Epub 2022 Jul 18. No abstract available.
Related Links
Access external resources that provide additional context or updates about the study.
official web site of the sponsor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PACAomics / IPC 2011-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.